Vaishali Pharma Limited (NSE: VAISHALI)
Source: Vaishali Pharma Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026) 📊 Stock Screeners
Vaishali Pharma Limited is an established enterprise operating in the global healthcare and pharmaceutical sector, focusing primarily on the marketing, trading, and export of a diverse portfolio of medical and healthcare products. The Company’s core business model spans multiple specialized verticals, enabling it to address varied healthcare requirements across domestic and international markets.
- Active Pharmaceutical Ingredients (APIs): High-purity active raw materials supplied to formulation manufacturers.
- Formulations: Finished pharmaceutical dosage forms including tablets, capsules, syrups, injectables, and ointments.
- Surgical Products: Comprehensive medical disposables and surgical consumables utilized in clinical settings.
- Veterinary Supplements: Specialized healthcare and nutritional formulations designed for animal husbandry.
📋 Quick Facts / Company Snapshot: Vaishali Pharma Limited (NSE: VAISHALI)
| Attribute | Disclosed Detail |
|---|---|
| Official Company Name | Vaishali Pharma Limited |
| Corporate Identity Number (CIN) | L52310MH2008PLC181632 |
| ISIN | INE972X01022 |
| NSE Symbol & BSE Scrip Code | NSE: VAISHALI |
| Date of Incorporation / Founding Year | 25th April, 2008 |
| Founders / Key Founding Figures | Mr. Atul Arvind Vasani and Mrs. Jagruti Atul Vasani |
| Registered Office & Corporate Headquarters | 706 to 709, 7th Floor, Aravali Business Center, R. C. Patel Road, Off Sodawala Lane, Borivali (West), Mumbai – 400092, Maharashtra, India |
| Telephone & Investor Relations Contact | cs@vaishalipharma.com |
| Chairman / Managing Director & CEO | Mr. Atul Vasani (Chairman & Managing Director), Mr. Hemant Damodar Pathak (Chief Executive Officer) |
| Chief Financial Officer (CFO) & Company Secretary (CS) | Mr. Dewansh Ajay Vasani (CFO), Ms. Vishwa Bipinbhai Mekhia (Company Secretary & Compliance Officer) |
| Promoter & Holding Group | Mr. Atul Arvind Vasani and Mrs. Jagruti Atul Vasani |
| Industry / Sector Classification | Pharmaceuticals, Healthcare, and Allied Products Sector |
| Total Employees / Workforce | 30 Permanent employees on the rolls as on March 31, 2026 |
| Countries / States Served | Domestic markets across India and international markets including Russia, the UAE, Madagascar, and Palestine |
| Statutory Auditors | Raman S. Shah & Associates, Chartered Accountants |
| Registrar and Share Transfer Agent (RTA) | Bigshare Services Private Limited |
🏢 The Corporate Identity: Vaishali Pharma Limited Overview, Promoters & History
The Big Picture: Business Model & Core Value Proposition
Vaishali Pharma Limited is an established enterprise operating in the global healthcare and pharmaceutical sector, focusing primarily on the marketing, trading, and export of a diverse portfolio of medical and healthcare products. The Company’s core business model spans multiple specialized verticals, enabling it to address varied healthcare requirements across domestic and international markets. By leveraging its extensive supply chain network, stringent quality assurance protocols, and established customer relationships, Vaishali Pharma Limited delivers reliable and cost-effective pharmaceutical solutions.
The enterprise functions as a comprehensive sourcing and distribution partner within the pharmaceutical ecosystem, bridging manufacturers and end-users across emerging and regulated international geographies. Through continuous process improvements, regulatory compliance, and strategic product diversification, the Company maintains a resilient operational framework designed to generate sustainable, long-term value for its stakeholders.
The Founders, Promoters & Their Legacy
The strategic direction and operational leadership of Vaishali Pharma Limited are steered by its promoter directors, Mr. Atul Arvind Vasani, who serves as the Chairman and Managing Director, and Mrs. Jagruti Atul Vasani, who serves as the Whole-Time Director. Their extensive experience in the pharmaceutical trading and export industry has been instrumental in guiding the Company through evolving market dynamics, global economic shifts, and regulatory transformations.
Supported by a professional executive management team—including Mr. Dewansh Ajay Vasani as Executive Director and Chief Financial Officer, and Mr. Hemant Damodar Pathak as Chief Executive Officer—the promoter group has cultivated a culture of integrity, transparency, and accountability. This leadership foundation has enabled the organization to forge durable commercial relationships and expand its operational footprint across multiple international territories.
The Journey: Corporate History & Key Milestones
Incorporated on April 25, 2008, as a private limited company under the provisions of the Companies Act, 1956, Vaishali Pharma Limited subsequently transitioned into a public limited company to support its expanding business scale. Over the years, the Company has systematically broadened its product offerings from basic pharmaceutical formulations to a comprehensive suite encompassing Active Pharmaceutical Ingredients (APIs), surgical products, veterinary supplements, and herbal and nutraceutical preparations.
A significant milestone in the Company’s capital market history includes the listing of its equity shares on the National Stock Exchange of India Limited (NSE) under the trading symbol VAISHALI. Further expanding its strategic footprint, during the financial year 2025–26, the Company increased its equity shareholding in Kesar Pharma Limited from 11.30% to 20.33%, establishing it as an associate company with effect from September 10, 2025.
The Corporate Umbrella & Group Structure
As of March 31, 2026, Vaishali Pharma Limited operates as a standalone corporate entity with one associate company within its structural umbrella. The Company does not have any direct subsidiaries or joint venture entities as of the reporting date. The associate entity, Kesar Pharma Limited, operates within the pharmaceutical manufacturing and allied domain, contributing to the broader strategic synergies of the group.
⚙️ The Business Engine: Segments, Brands, Products & Operations
The Core Divisions & Segment Revenue Breakdown
Vaishali Pharma Limited operates primarily within a single unified business segment focused on the trading, marketing, and export of pharmaceutical and healthcare products. Consequently, discrete segment-wise reporting for distinct business verticals is not separately maintained under Ind AS 108, as the entire operations are viewed by the chief operating decision maker as a single reportable operating segment.
The Product & Service Catalog (and Operational KPIs)
The Company maintains a diversified product catalog designed to cater to human healthcare, veterinary care, and surgical requirements. Its product segments comprise Active Pharmaceutical Ingredients (APIs), finished pharmaceutical formulations across various dosage forms, surgical dressings and hospital consumables, veterinary dietary supplements, and herbal and nutraceutical health products.
- Active Pharmaceutical Ingredients (APIs): High-purity active raw materials supplied to formulation manufacturers.
- Formulations: Finished pharmaceutical dosage forms including tablets, capsules, syrups, injectables, and ointments.
- Surgical Products: Comprehensive medical disposables and surgical consumables utilized in clinical settings.
- Veterinary Supplements: Specialized healthcare and nutritional formulations designed for animal husbandry.
- Herbal & Nutraceutical Products: Plant-based remedies and nutritional health supplements supporting holistic wellness.
Mapping the Domestic & Global Reach (India vs. Exports)
Vaishali Pharma Limited maintains a balanced commercial presence across domestic Indian markets and international territories. International operations are characterized by exports to several emerging global economies, supported by established logistics and regulatory compliance frameworks.
| Market Geography | Revenue (₹ in Crores) | % Share of Total Revenue |
|---|---|---|
| Domestic Sales (India) | 64.99 | 57.71% |
| Export Sales (International) | 39.77 | 35.32% |
| Commission Income & Export Incentives | 4.02 | 3.57% |
| Total Income from Operations | 112.61 | 100.00% |
Note: International export destinations serviced by the Company include Russia, the United Arab Emirates (UAE), Madagascar, Palestine, and other emerging global markets.
The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices
The Company’s registered and corporate office is strategically situated at Borivali West, Mumbai, Maharashtra, providing centralized administrative control, corporate governance oversight, and commercial coordination. Operational logistics, sourcing, and quality control functions are managed through established commercial channels and partnered manufacturing infrastructure.
📊 The Financial Health: The Numbers Simplified
Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)
The consolidated financial performance of Vaishali Pharma Limited for the financial year ended March 31, 2026, reflects steady top-line expansion and improved operational profitability compared to preceding periods.
| Financial Particulars (₹ in Crores) | FY 2025-26 |
|---|---|
| Revenue from Operations | 108.77 |
| Other Income | 3.84 |
| Total Income | 112.61 |
| Purchases of Stock-in-Trade / Cost of Materials Consumed | 93.71 |
| Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress | 1.41 |
| Employee Benefits Expense | 2.91 |
| Finance Costs | 1.96 |
| Depreciation and Amortisation Expense | 0.60 |
| Other Expenses | 6.62 |
| Total Expenses | 107.22 |
| Profit Before Tax | 5.39 |
| Tax Expense (Current Tax & Deferred Tax) | 1.36 |
| Profit After Tax (PAT) | 4.16 |
| Share of Profit from Associate Company | 0.13 |
| Other Comprehensive Income (OCI) (Net of Tax) | 0.03 |
| Total Comprehensive Income for the Year | 4.20 |
| Basic & Diluted Earnings Per Share (EPS in ₹) | 0.32 |
Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)
The consolidated financial position of the group as at March 31, 2026, details a robust asset base supported by working capital lines and shareholder equity.
| Balance Sheet Particulars (₹ in Crores) | As at March 31, 2026 |
|---|---|
| Property, Plant and Equipment | 0.90 |
| Right of Use Assets | 0.26 |
| Intangible Assets & Intangible Assets under Development | 0.79 |
| Non-Current Investments | 5.56 |
| Other Non-Current Financial & Non-Financial Assets | 2.92 |
| Deferred Tax Assets (Net) | 0.15 |
| Total Non-Current Assets | 10.43 |
| Inventories | 3.40 |
| Trade Receivables | 50.77 |
| Cash and Cash Equivalents | 1.11 |
| Bank Balances Other than Cash and Cash Equivalents | 0.32 |
| Other Current Financial Assets | 32.09 |
| Current Tax Assets (Net) & Other Current Assets | 25.27 |
| Total Current Assets | 112.96 |
| Total Assets | 123.39 |
| Equity Share Capital | 26.09 |
| Other Equity | 43.02 |
| Total Equity | 69.12 |
| Non-Current Borrowings | 5.69 |
| Non-Current Provisions | 0.29 |
| Total Non-Current Liabilities | 5.98 |
| Current Borrowings | 12.84 |
| Current Lease Liabilities | 0.36 |
| Trade Payables | 21.18 |
| Other Current Financial & Non-Financial Liabilities | 12.47 |
| Current Provisions & Income Tax Liabilities | 1.45 |
| Total Current Liabilities | 48.30 |
| Total Liabilities | 54.28 |
| Total Equity and Liabilities | 123.39 |
Cash Flow: Tracking the Money Movement
The consolidated statement of cash flows highlights the generation and utilization of liquid resources across operating, investing, and financing activities during the fiscal year.
| Cash Flow Particulars (₹ in Crores) | Year ended March 31, 2026 |
|---|---|
| Net Cash from Operating Activities | 0.44 |
| Net Cash Used in Investing Activities | (5.46) |
| Net Cash from Financing Activities | 4.61 |
| Net Increase / (Decrease) in Cash and Cash Equivalents | (0.41) |
| Cash and Cash Equivalents at Beginning of Year | 1.84 |
| Cash and Cash Equivalents at End of Year | 1.43 |
👥 Power & Control: Corporate Governance, Leadership & Ownership
The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)
The Board of Directors comprises experienced professionals across executive and independent capacities, ensuring robust governance and adherence to regulatory standards.
| Name of Director / KMP | Designation / Role | DIN | Category |
|---|---|---|---|
| Mr. Atul Arvind Vasani | Chairman & Managing Director | 02107085 | Executive Director |
| Mrs. Jagruti Atul Vasani | Whole-Time Director | 02107094 | Executive Director |
| Mr. Dewansh Ajay Vasani | Executive Director & Chief Financial Officer | 08111804 | Executive Director |
| Mr. Manish Bhagwandas Ved | Non-Executive Independent Director | 08654674 | Independent Director |
| Mr. Pratik Vikram Jakhelia | Non-Executive Independent Director | 07726752 | Independent Director |
| Mr. Bhaveshkumar Popatlal Upadhyay | Non-Executive Independent Director | 08384922 | Independent Director |
| Mr. Hemant Damodar Pathak | Chief Executive Officer | — | Key Managerial Personnel |
| Ms. Vishwa Bipinbhai Mekhia | Company Secretary & Compliance Officer | — | Key Managerial Personnel |
Who Owns the Stock? Shareholding Pattern
The shareholding distribution of Vaishali Pharma Limited as on March 31, 2026, reflects promoter commitment alongside institutional and public retail participation.
| Category of Equity Shareholder | Number of Equity Shares Held | Percentage of Holding (%) |
|---|---|---|
| Promoters (Mr. Atul Arvind Vasani & Mrs. Jagruti Atul Vasani) | 4,12,35,290 | 31.61% |
| Non-Resident Indians (NRIs) / OCBs / Foreign Nationals | 445,480 | 0.34% |
| Bodies Corporates (Non-Institutional) | 35,09,810 | 2.69% |
| Indian Public and Others | 8,49,59,452 | 65.12% |
| Clearing Members | 312,098 | 0.24% |
| Grand Total | 13,04,62,130 | 100.00% |
🗺️ The Corporate Family Tree: Group Structure & Strategic Investments
Subsidiaries, Associates, & Joint Ventures (Form AOC-1)
In accordance with Form AOC-1, the Company holds an associate stake in Kesar Pharma Limited as of March 31, 2026.
| Name of Associate Entity | Relationship | Country | % Shareholding | Latest Audited Net Worth (₹) |
|---|---|---|---|---|
| Kesar Pharma Limited | Associate Company | India | 20.33% | ₹29,58,02,340 |
🎯 The Strategic Outlook: Competitive Moats, Risks & Future Growth Plans
Competitive Advantages & Economic Moats
The Company derives its competitive strength from a diversified product portfolio, established global sourcing networks, and enduring relationships with customers across multiple international jurisdictions. Its ability to supply specialized pharmaceutical formulations, APIs, and surgical products provides operational flexibility in responding to shifting healthcare demands.
What Could Go Wrong? Key Challenges & Business Risks
Key business risks identified by the management include foreign exchange rate volatility, regulatory developments across export markets, supply chain disruptions, pricing pressures, and intense competition within the pharmaceutical trading sector. The Company actively monitors these risk factors through prudent financial management and structured internal control mechanisms.
The Next Chapter: Growth, Order Pipeline & CapEx Initiatives
Looking ahead, Vaishali Pharma Limited remains focused on expanding its international market presence, optimizing operational efficiencies, strengthening its core product portfolio, and identifying new avenues for long-term revenue growth. Strategic investments, such as its association with Kesar Pharma Limited, align with the organization’s broader objective of building a resilient and globally competitive healthcare enterprise.
The Verdict: Strategic Outlook & Conclusion
Through disciplined financial governance, rigorous quality assurance, and continued geographical diversification, Vaishali Pharma Limited is well-positioned to capitalize on emerging opportunities within the global pharmaceutical ecosystem while delivering sustainable value to its stakeholders.
Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.
Official Site: https://www.vaishalipharma.com
SCHEMA
[googlesitekit-end-of-content]
SCHEMA
[googlesitekit-end-of-content]
SCHEMA
[googlesitekit-end-of-content]
SCHEMA
[googlesitekit-end-of-content]
SCHEMA
[googlesitekit-end-of-content]
SCHEMA
[googlesitekit-end-of-content]
SCHEMA
[googlesitekit-end-of-content]
SCHEMA
[googlesitekit-end-of-content]
SCHEMA
[googlesitekit-end-of-content]
SCHEMA
[googlesitekit-end-of-content]